SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-21-058138
Filing Date
2021-04-30
Accepted
2021-04-30 07:00:57
Documents
6
Period of Report
2021-06-08

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2114196-1_def14a.htm DEF 14A 1118903
2 GRAPHIC lg_trilliumtherapeuti-4clr.jpg GRAPHIC 55718
3 GRAPHIC tm2114196d1-pc_ceo4c.jpg GRAPHIC 97056
4 GRAPHIC tm2114196d1-lc_performancbw.jpg GRAPHIC 109111
5 GRAPHIC tm2114196d1-proxy_trilpg14c.jpg GRAPHIC 650028
6 GRAPHIC tm2114196d1-proxy_trilpg2bw.jpg GRAPHIC 551353
  Complete submission text file 0001104659-21-058138.txt   3122354
Mailing Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9
Business Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 (416) 595-0627
Trillium Therapeutics Inc. (Filer) CIK: 0001616212 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36596 | Film No.: 21873675
SIC: 2834 Pharmaceutical Preparations